title: Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average five-year follow-up study.
abstract: The objectives of this study were to determine whether recombinant human bone morphogenetic protein-2 (rhBMP-2) can be used as the sole stimulator of osteogenesis with success equal to an autologous graft in posterolateral lumbar fusion (PLF) at the same level and to describe the progress until bone union. This study included 11 patients who underwent PLF of L4-5. On the right side, only rhBMP-2, for which polylactic/glycolic acid (PLGA) was used as a carrier, was used, whereas, on the left side, autogenous bone was used. The bone union rate was 73 and 82% at 12 and 24 months after surgery, respectively, on the right BMP side, while the rate on the autogenous bone side was 91%. There was no statistically significant difference in the bone union rate. rhBMP-2 can be used as the sole source of osteogenesis with success equivalent to an autologous graft of the PLF.
authors.affiliation: Orthopaedics, Nagoya University, Nagoya, Japan.
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Katayama
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Matsuyama
authors.forename: Hisatake
authors.initials: H
authors.lastname: Yoshihara
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Sakai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakamura
authors.forename: Shiro
authors.initials: S
authors.lastname: Imagama
authors.forename: Zenya
authors.initials: Z
authors.lastname: Ito
authors.forename: Norimitsu
authors.initials: N
authors.lastname: Wakao
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Kamiya
authors.forename: Yasutsugu
authors.initials: Y
authors.lastname: Yukawa
authors.forename: Tokumi
authors.initials: T
authors.lastname: Kanemura
authors.forename: Koji
authors.initials: K
authors.lastname: Sato
authors.forename: Hisashi
authors.initials: H
authors.lastname: Iwata
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishiguro
mesh_terms: D000328:Adult; D000368:Aged; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology / Q000627:therapeutic use*; D016025:Bone Transplantation / Q000379:methods; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019344:Lactic Acid; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D010012:Osteogenesis / Q000187:drug effects; D017063:Outcome Assessment, Health Care; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011446:Prospective Studies; D011859:Radiography; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D013122:Spinal Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery*; D013123:Spinal Fusion / Q000379:methods*; D016896:Treatment Outcome
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D011994:Recombinant Proteins; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid